Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical ...

Sagimet Biosciences shares rose after the company's acne treatment met all primary and secondary endpoints in a phase 3 trial. The stock gained 17% to $8.55 Friday. Shares are up 87% this year.

The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to ...

That’s not all. It is also important to identify hormonal issues such as Polycystic Ovary Syndrome (PCOS) or hyperandrogenism ...

My first unwelcome visitors took residence on my face in sixth grade. My acne stayed pretty bad throughout middle school, but ...

Queens esthetician Priscila Pantosin is an expert in helping her clients bring out their best glow ever since she first ...

A young woman shares her emotional 15-year journey with hidradenitis suppurativa, chronic skin inflammation for which ...

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often ...

‘It’s a true hero ingredient,’ says Dominic Roach, advanced artistic director at Aveda UK. ‘Moringa oil provides maximum ...

The first time Joey Carlsen Martinez came to Memorial Sloan Kettering Cancer Center (MSK), he was in terrible shape. He had a ...

Experts weigh in on whether at-home micro-current devices live up to their claims. Discover which tools actually sculpt, lift ...

Home remedies often suggest lemon for skin but dermatologists warn against it. Direct application causes irritation, burns, and sun sensitivity. The h ...